FDA Accelerates Review of Psychedelic Therapies as U.S. Signals Shift in Mental Health Treatment Policy

By Zoey

The U.S. Food and Drug Administration announced a significant policy move aimed at expediting the development of experimental psychedelic-based treatments for mental health disorders, marking a notable shift in federal approach under the administration of Donald Trump.

The agency confirmed it will grant ultra-fast review pathways to three investigational drugs derived from or related to psychedelic compounds, targeting conditions such as treatment-resistant depression and post-traumatic stress disorder. The decision follows a recent executive order signed by Trump directing federal agencies to accelerate research and reconsider regulatory barriers surrounding psychedelics, which remain classified as illegal substances under U.S. law.

Under the new initiative, the FDA has issued priority review vouchers to companies developing therapies based on psilocybin—the psychoactive compound found in so-called “magic mushrooms”—for patients suffering from severe forms of depression that have not responded to existing treatments. A third voucher was awarded to a developer working on methylone, a compound chemically related to MDMA, for use in treating PTSD.

Although the agency did not disclose the names of the companies involved, officials emphasized that the vouchers are intended to dramatically compress the timeline for regulatory review. While standard drug evaluations can take several months or longer, the accelerated pathway aims to reduce that timeframe to a matter of weeks, potentially speeding access to new therapies if they prove safe and effective in clinical trials.

Marty Makary said the initiative reflects an urgency to address persistent gaps in mental health treatment, particularly for populations such as military veterans who often face high rates of trauma-related conditions. He noted that exploring emerging therapies is critical in light of the limitations of current pharmaceutical options.

The move represents one of the most assertive federal actions to date in support of psychedelic research, a field that has historically faced significant regulatory and legal barriers. Substances such as psilocybin, LSD, and MDMA are classified as Schedule I drugs in the United States, a designation reserved for compounds considered to have a high potential for abuse and no accepted medical use.

Despite these restrictions, interest in psychedelics has grown rapidly in recent years, driven by early-stage clinical research suggesting potential benefits in treating depression, addiction, and trauma-related disorders. This momentum has been further amplified by advocacy from segments of the public and political figures aligned with the administration.

Robert F. Kennedy Jr. has been a prominent supporter of expanding access to alternative mental health treatments, including psychedelics. He has previously indicated that federal health agencies aim to make such therapies available for certain conditions within a relatively short timeframe, signaling a broader policy pivot.

The FDA’s decision is also likely to intensify scrutiny of its priority review voucher program, formally known as the Commissioner’s National Priority Voucher initiative. Critics, particularly among Democratic lawmakers, have raised concerns that the program may be used to favor companies with political connections or those aligned with administration priorities, rather than strictly scientific considerations.

In a parallel development, the FDA authorized early-stage testing of a drug derived from ibogaine, a powerful naturally occurring psychedelic sourced from an African plant. The investigational treatment is being studied for alcohol use disorder, a condition with limited effective treatment options.

Ibogaine itself is associated with significant risks, including potentially dangerous cardiac side effects, as well as intense hallucinogenic experiences. However, the company developing the new therapy, DemeRx, says its formulation is based on a metabolite of ibogaine that may reduce these risks while preserving therapeutic benefits.

The company’s founder, Deborah Mash, has been studying ibogaine-related compounds for decades. Her earlier research efforts in the 1990s faced funding challenges after federal agencies declined to support further investigation, effectively stalling progress in the field at the time.

The renewed federal interest comes amid increasing political and cultural attention on psychedelics. Public figures, including podcast host Joe Rogan, have played a role in bringing the topic into mainstream discourse. Rogan has publicly discussed ibogaine and its potential therapeutic applications, including its use in treatment settings outside the United States.

At a recent White House event, Rogan described direct communication with Trump about accelerating approval for psychedelic treatments, reflecting the growing influence of nontraditional advocates in shaping policy discussions around emerging medical therapies.

Meanwhile, the private sector has moved quickly to capitalize on renewed interest. A wave of biotech startups, often backed by venture capital and technology investors, has entered the field in pursuit of FDA approval for various psychedelic compounds. Among them are firms supported by high-profile investors such as Peter Thiel, who has funded research into MDMA and related substances through companies like Atai Life Sciences.

The convergence of political support, scientific exploration, and financial investment has transformed what was once a fringe area of research into a rapidly evolving sector within the pharmaceutical industry.

Even so, significant hurdles remain. Clinical trials must still demonstrate safety, efficacy, and consistent outcomes before any of these treatments can receive full regulatory approval. Questions also persist  long-term effects, appropriate therapeutic settings, and safeguards to prevent misuse.

The FDA’s latest actions suggest a willingness to navigate these uncertainties in pursuit of new solutions to persistent mental health challenges. As the agency accelerates its review processes, the coming months are expected to be pivotal in determining whether psychedelic-based therapies can transition from experimental status to mainstream medical use.